Kaijing Pharmaceutical

Kaijing Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on developing innovative small-molecule kinase inhibitors. The company's primary research areas include immunology and oncology, with a focus on addressing unmet medical needs in autoimmune disorders. Its lead product candidate, K-001, is a highly selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for rheumatoid arthritis and atopic dermatitis. Additionally, the company is advancing K-804, a Tyrosine kinase 2 (TYK2) inhibitor, for the treatment of psoriasis and other inflammatory conditions. Kaijing Pharmaceutical leverages its proprietary drug discovery platform to design therapies with improved safety and efficacy profiles. The company has established a robust pipeline of candidates targeting various kinase-mediated signaling pathways.